Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
In recent years, tremendous progress has been made in the battle against malaria.To date, the malaria box has been shared with more than 250 research groups in 30 countries around the world, and has led to the initiation of several new drug-discovery programs across a range of neglected diseases.One example of this type of collaboration is the world's first "open lab" for research into diseases of the developing world, established in 2010 at GSK's research site in Tres Cantos, Spain.Three potential new treatments for malaria being developed by GSK (two in partnership with MMV) are progressing to clinical trials.If successful, it will be the first treatment for relapsing malaria approved in more than 60 years.A world first, it is the culmination of three decades of research and unprecedented levels of collaboration between GSK, the PATH Malaria Vaccine Initiative, and African research centers.Each positive statistic is balanced by the stark reality that there are still around 200 million cases of malaria each year, killing nearly 500,000 people, the vast majority of whom are children under the age of five.
FOLLOW THIS ARTICLE